Article
Treatment with a farnesyltransferase inhibitor improves survival in mice with a Hutchinson-Gilford progeria syndrome mutation.
Biochimica et biophysica acta - 1 Jan 2000
Yang Shao H, Qiao Xin, Fong Loren G, Young Stephen G
Abstract excerpt
Hutchinson-Gilford progeria syndrome (HGPS) is a progeroid syndrome characterized by multiple aging-like disease phenotypes. We recently reported that a protein farnesyltransferase inhibitor (FTI) improved several disease phenotypes in mice with a HGPS mutation (Lmna(HG/+)). Here, we investigated the impact of an FTI on the survival of Lmna(HG/+) mice. The FTI significantly improved the survival of both male and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.